Inducible promoter
By inserting the TetO operator before and after the promoter TATA box and combining the AAV vector, the problem of low transcriptional regulation efficiency in the existing technology when the external environment changes is changed, and efficient induction of polynucleotide sequences is achieved, which improves the Application potential of biological products production.
Patent Information
- Application Number
- CN202411303723.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-05
- Publication Date
- 2024-11-01
AI Technical Summary
The existing promoters are difficult to effectively initiate or stop transcription of target genes when the external environment changes, which limits the application potential of life science research and biological product production.
The modified inducible promoter is formed by inserting multiple TetO operators before and/or after the unmodified promoter TATA frame, and combining the AAV vector and inducer to achieve inducible expression of the polynucleotide sequence.
It significantly improves the expression level of inducible promoters in the presence of inducible agents, reduces the background leakage expression, achieves efficient induced expression of the gene of interest, and enhances its application prospects in life science research and biological products production.
Smart Images

Figure CN118879705A_ABST
Abstract
Description
[0001] This application is a divisional application of the Chinese invention patent application with application date of June 5, 2024, application number 2024107277023, and invention name “A kind of inducible promoter”. Technical Field
[0002] The present invention belongs to the field of biomedicine, and in particular relates to an inducible promoter. Background Art
[0003] The promoter is a DNA sequence located upstream of the 5' end of the structural gene, which can activate RNA polymerase, allowing it to accurately bind to the template DNA and have the specificity of transcription initiation. Inducible promoters can start or stop the transcription of the target gene in response to changes in the external environment, and have broad application prospects in life science research and the production of biological products. Summary of the invention
[0004] The present disclosure provides a modified promoter, wherein a TetO operator is inserted before and / or after the TATA box of an unmodified promoter, wherein the copy number of the TetO operator is more than one, and the unmodified promoter is selected from CMV, EF1a, MNDU3, hCEF1, RSV, SV40, E1A, E2A or E4.
[0005] In some embodiments, compared to the unmodified promoter, the TetO operator is inserted 1-2 bp before the TATA box and / or 2-10 bp after the TATA box.
[0006] In some embodiments, compared to an unmodified promoter, 1) The 2 bp before the TATA box and the 2-10 bp after the TATA box are respectively inserted with a TetO operator, wherein the copy number of the TetO operator is more than one, and the unmodified promoter is selected from CMV, EF1a, MNDU3, hCEF1, RSV or SV40; or 2) A TetO operator is inserted 2-10 bp after the TATA box, wherein the copy number of the TetO operator is more than two, and the unmodified promoter is selected from EF1a, MNDU3, hCEF1, RSV or SV40; or 3) The TetO operator is inserted into the 2 bp before the TATA box and the 2-10 bp after the TATA box, respectively, wherein the copy number of the TetO operator is more than one, and the unmodified promoter is selected from E1A, E2A or E4.
[0007] In some specific embodiments, the modified promoter comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-19 or a sequence having at least 70% identity thereto.
[0008] In another aspect, the present disclosure provides a nucleic acid construct comprising: (1) Polynucleotide sequence of interest; (2) A transcriptional regulatory element operably linked to a polynucleotide sequence of interest, wherein the transcriptional regulatory element comprises a modified promoter as described above, and the transcriptional regulatory element is located upstream of the polynucleotide sequence of interest.
[0009] In another aspect, the present disclosure provides a vector comprising the modified promoter or nucleic acid construct described above.
[0010] In some embodiments, the vector is a viral vector.
[0011] In some embodiments, the viral vector is an AAV vector, an adenoviral vector, or a lentiviral vector.
[0012] In another aspect, the present disclosure provides an adeno-associated virus (AAV) particle comprising the vector as described above and a capsid protein.
[0013] In some specific embodiments, the AAV is selected from the group consisting of wild-type AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrh.8, AAVrh.10, AAVrh.39, AAVHSC15, AAVHSC17 and AAV serotypes modified based on AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrh.8, AAVrh.10, AAVrh.39, AAVHSC15, and AAVHSC17.
[0014] In another aspect, the present disclosure provides a cell for producing an adeno-associated virus (AAV), comprising the nucleic acid construct or vector as described above.
[0015] In another aspect, the present disclosure provides use of a modified promoter, nucleic acid construct or cell as described above for increasing the level of induced expression of a polynucleotide sequence of interest.
[0016] In another aspect, the present disclosure provides a method for inducing expression of a protein of interest in vitro, comprising: using the modified promoter, nucleic acid construct, or cell as described above to induce expression of a polynucleotide sequence of interest in the presence of an inducer. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] The present disclosure can be more fully understood with reference to the following drawings.
[0018] Figure 1 The figure shows the inducible expression effects of different inducible promoters on the Luciferase-P2A-zsGreen dual-purpose genes.
[0019] Figure 2 The figure shows the inducible expression effect of different adenovirus gene inducible promoters on the Luciferase-P2A-zsGreen dual-purpose gene.
[0020] Figure 3 The graph shows the effects of different adenovirus E1A inducible promoters on the inducible expression of adenovirus E1A gene. DETAILED DESCRIPTION
[0021] The following description of the present disclosure is intended only to illustrate various different embodiments of the present disclosure. Therefore, the specific modifications discussed should not be interpreted as limiting the scope of the present disclosure. It is obvious to those skilled in the art that various different equivalents, changes and modifications can be made without departing from the scope of the present disclosure, and it should be understood that these equivalent embodiments will be included herein. All references cited herein, including publications, patents and patent applications, are incorporated herein by reference in their entirety.
[0022] In the present disclosure, "the copy number of the TetO operator" means the total number of copies of the TetO operator inserted into the modified promoter.
[0023] On the one hand, the present disclosure provides a modified promoter, in which a TetO operator is inserted before the TATA box and / or after the TATA box compared to an unmodified promoter, wherein the copy number of the TetO operator is more than one, preferably 2 to 4, and the unmodified promoter is selected from CMV, EF1a, MNDU3, hCEF1, RSV, SV40, E1A, E2A or E4.
[0024] In some embodiments, compared to the unmodified promoter, the TetO operator is inserted 1-2 bp before the TATA box and / or 2-10 bp after the TATA box.
[0025] In some embodiments, compared to an unmodified promoter, 1) A TetO operator is inserted into 1-2 bp before the TATA box and 2-10 bp after the TATA box, respectively, wherein the copy number of the TetO operator is more than one (preferably one before and after the TATA box), and the unmodified promoter is selected from CMV, EF1a, MNDU3, hCEF1, RSV or SV40; or 2) A TetO operator is inserted 2-10 bp after the TATA box, wherein the copy number of the TetO operator is more than two (preferably 2), and the unmodified promoter is selected from EF1a, MNDU3, hCEF1, RSV or SV40; or 3) The TetO operator is inserted into the 2 bp before the TATA box and the 2-10 bp after the TATA box, respectively, wherein the copy number of the TetO operator is more than one (preferably 2), and the unmodified promoter is selected from E1A, E2A or E4.
[0026] In one embodiment, two copies of TetO operator are inserted 9 bp after the TATA box of CMV promoter. In one embodiment, one copy of TetO operator is inserted 1 bp before the TATA box of CMV promoter, and another copy of TetO operator is inserted 9 bp after the TATA box of CMV promoter.
[0027] In one embodiment, two copies of TetO operator are inserted 2 bp after the TATA box of EF1a promoter. In one embodiment, one copy of TetO operator is inserted 2 bp before the TATA box of EF1a promoter, and another copy of TetO operator is inserted 2 bp after the TATA box of EF1a promoter.
[0028] In one embodiment, one copy of TetO operator is inserted 2 bp before the TATA box of the MNDU3 promoter, and another copy of TetO operator is inserted 2 bp after the TATA box of the MNDU3 promoter. In one embodiment, two copies of TetO operator are inserted 2 bp after the TATA box of the MNDU3 promoter.
[0029] In one embodiment, two copies of TetO operator are inserted 2 bp after the TATA box of hCEF1 promoter. In one embodiment, one copy of TetO operator is inserted 2 bp before the TATA box of hCEF1 promoter, and another copy of TetO operator is inserted 2 bp after the TATA box of hCEF1 promoter.
[0030] In one embodiment, two copies of TetO operator are inserted into the RSV promoter TATA box 2 bp later. In one embodiment, two copies of TetO operator are inserted into the SV40 promoter TATA box 2 bp later.
[0031] In one embodiment, two copies of the TetO operator are inserted 2 bp before the TATA box of the E1A promoter. In one embodiment, one copy of the TetO operator is inserted 2 bp before the TATA box of the E1A promoter, and the other copy of the TetO operator is inserted 2 bp after the TATA box of the E1A promoter. In one embodiment, two copies of the TetO operator are inserted 2 bp after the TATA box of the E1A promoter.
[0032] In one embodiment, two copies of the TetO operator are inserted 2 bp before the TATA box of the E2A promoter. In one embodiment, one copy of the TetO operator is inserted 2 bp before the TATA box of the E2A promoter, and the other copy of the TetO operator is inserted 2 bp after the TATA box of the E2A promoter. In one embodiment, two copies of the TetO operator are inserted 2 bp after the TATA box of the E2A promoter.
[0033] In one embodiment, two copies of the TetO operator are inserted 2 bp before the TATA box of the E4 promoter. In one embodiment, one copy of the TetO operator is inserted 2 bp before the TATA box of the E4 promoter, and the other copy of the TetO operator is inserted 2 bp after the TATA box of the E4 promoter. In one embodiment, two copies of the TetO operator are inserted 2 bp after the TATA box of the E4 promoter.
[0034] In some embodiments, the sequence of the TetO operator may be, for example, TCCCTATCAGTGATAGAGA (SEQ ID NO: 21). In some embodiments, there is at least a 2 bp interval between the two copies of the TetO operator, and the interval sequence is preferably TC.
[0035] In some embodiments, the modified promoter comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-19 or a sequence having at least 70%, 80%, 90%, 93%, 95%, 98%, 99%, or 99.5% or more identity thereto.
[0036] In another aspect, the present disclosure provides a nucleic acid construct comprising: (1) Polynucleotide sequence of interest; (2) A transcriptional regulatory element operably linked to a polynucleotide sequence of interest, wherein the transcriptional regulatory element comprises a modified promoter as described above, and the transcriptional regulatory element is located upstream of the polynucleotide sequence of interest.
[0037] In another aspect, the present disclosure provides a vector comprising the modified promoter or nucleic acid construct as described above.
[0038] In some embodiments, the vector is a viral vector.
[0039] In some embodiments, the viral vector is an AAV vector, an adenoviral vector, or a lentiviral vector.
[0040] In another aspect, the present disclosure provides an adeno-associated virus (AAV) particle comprising the vector as described above and a capsid protein.
[0041] In some embodiments, the AAV is selected from the group consisting of serotype 9, 8, 1, 2, 3, 3B, 4, 5, 6, 7, 10, 11, 12, 13, rh10 or hu37 and any AAV serotype isolated from human and non-human mammals or variants thereof.
[0042] In another aspect, the present disclosure provides a cell for producing an adeno-associated virus (AAV), comprising the nucleic acid construct or vector as described above.
[0043] In another aspect, the present disclosure provides use of a modified promoter, nucleic acid construct, or cell as described above for increasing the level of induced expression of a polynucleotide sequence of interest.
[0044] In another aspect, the present disclosure provides a method for inducing expression of a protein of interest in vitro, comprising: using the modified promoter, nucleic acid construct, or cell as described above to induce expression of a polynucleotide sequence of interest in the presence of an inducer.
[0045] As used herein, the terms "nucleotide" and "polynucleotide" are used interchangeably and refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. Thus, the term includes, but is not limited to, single-stranded, double-stranded, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or polymers comprising, consisting essentially of, or consisting of purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural or derived nucleotide bases.
[0046] The term "promoter" as used herein means a control sequence, which is a region of a polynucleotide sequence that controls the initiation and rate of transcription of a coding sequence, such as a gene or a transgene. Promoters can be constitutive, inducible, repressible or tissue-specific.
[0047] The term "vector" as used herein refers to a nucleic acid comprising, consisting essentially of, or consisting of a complete replicon, such that the vector can be replicated when placed into a cell by, for example, a transfection, infection, or transformation process. It is understood in the art that once inside a cell, the vector can replicate as an extrachromosomal (episomal) element, or can be integrated into a host cell chromosome. The vector may include nucleic acids derived from retroviruses, adenoviruses, herpes viruses, baculoviruses, modified baculoviruses, papillomaviruses, AAV viral vectors, lentiviral vectors, adenoviral vectors, alphaviral vectors, and the like, preferably, the vector described herein is selected from an AAV vector, an adenoviral vector, or a lentiviral vector.
[0048] As used herein, the term "adeno-associated virus" or "AAV" refers to members of the class of viruses associated with that name and belonging to the genus Dependoviridae of the family Parvoviridae. Adeno-associated virus is a single-stranded DNA virus that grows exclusively in cells, where certain functions are provided by a co-infecting helper virus. All AAV serotypes clearly display a homologous repGene-mediated very similar replication characteristics; and all carry three related capsid proteins. At least 13 naturally occurring AAV serotypes numbered in sequence are known in the art. Non-limiting exemplary serotypes used in the methods disclosed herein include any of these 13 serotypes, such as AAV2, AAV8, AAV9, or variant serotypes such as AAV-DJ and AAV PHP.B. AAV particles contain three major viral proteins VP1, VP2 and VP3, and are essentially composed of or composed of the proteins. In an embodiment, the AAV comprises an AAV capsid protein selected from the group consisting of AAVPHP.B, AAVrh74, AAV 110, AAV 204, AAV 214, AAV 214A, AAV 214e, AAV 214e8, AAV 214e9, AAV 214e10, AAV ITB102_45 and AAV 214AB. In an embodiment, AAV refers to serotypes AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrh.8, AAVrh.10, AAVrh.39, AAVHSC15, AAVHSC17, and novel AAV serotypes modified based on AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrh.8, AAVrh.10, AAVrh.39, AAVHSC15, AAVHSC17, or any one of the AAV serotypes isolated from human and non-human mammals, or variants thereof.
[0049] Example The following examples are illustrative only and are not intended to limit the scope or content of the present invention in any way.
[0050] Detection of Zsgreen and Luciferase expression The promoter plasmid and the regulatory element plasmid were co-transfected into HEK293T cells using FectoVIR-AAV transfection reagent (Polyplus 120-100, the same below). The inducing agent was added within 4-24 h after transfection to induce the expression of the target gene. 72 h after transfection, the Zsgreen fluorescence was observed and photographed under a fluorescence microscope. In addition, the well plate cells were harvested and lysed, and the lysate was diluted in a certain proportion and then the Luciferase detection reagent was added, and the chemiluminescence intensity was detected on an ELISA instrument.
[0051] E1A expression detection The promoter plasmid and the regulatory element plasmid were co-transfected into huh7 cells using FectoVIR-AAV transfection reagent. The induction agent was added within 4-24 hours after transfection to induce the expression of the target gene. 72 hours after transfection, the cells were harvested and lysed, and the lysate was subjected to Western Blot to detect the expression of E1A, and the detection antibody was Purified Mouse Anti-Adenovirus Type 5 E1A (BD 554155).
[0052] Example 1: Screening for exogenous inducible promoters (1) Construction of exogenous inducible promoter Select a variety of commonly used exogenous promoters, insert TetO operators 1-2 bp before or 2-10 bp after the TATA box of these promoters, and construct these inducible promoters in front of the Luciferase-P2A-zsGreen dual-purpose gene expression frame to construct the plasmids shown in Table 1 below.
[0053] Table 1
[0054] In the table above, capital letters represent TetO sequences and bold represents the TATA box.
[0055] (2) Screening of exogenous inducible promoters The inducible promoter plasmids of each version in Table 1 were combined with the TetR-Krab regulatory element plasmid (Szulc, J. et al. Aversatile tool for conditional gene expression and knockdown. Nat Methods ,3,109-116 (2006)) were co-transfected in HEK293T cells and the expression of Luciferase was compared when the inducer DOX (doxycycline) was added after transfection. The results are as follows Figure 1 The chemiluminescence intensity without the inducer DOX was compared and the induction multiple after the inducer DOX was added was calculated. The results are shown in Table 2.
[0056] Table 2
[0057] From the above results, it can be seen that the constructed multiple versions of inducible promoters (such as LYR1P052, LYR1P053, LYR1P057, LYR1P063, LYR1P065) have good induced expression effects. Compared with the existing technology, the background before induction is lower and the induction multiple is close to or better.
[0058] Example 2: Screening for adenovirus gene inducible promoters (1) Construction of adenovirus gene inducible promoter The promoters of adenovirus genes E1A, E2A, and E4 were selected, TetO operators were inserted near the TATA boxes of these promoters, and these inducible promoters were constructed in front of the Luciferase-P2A-zsGreen dual-purpose gene expression frame to construct the plasmids shown in Table 3 below.
[0059] Table 3
[0060] In the table above, capital letters represent TetO sequences and bold represents the TATA box.
[0061] (2) Screening of exogenous inducible promoters The inducible promoter plasmids of each version in Table 3 were co-transfected with the TetR-Krab regulatory element plasmid in HEK293T cells, and the expression of luciferase was compared when the inducer DOX was added after transfection. The results are shown in Table 3. Figure 2 The chemiluminescence intensity without the inducer DOX was compared and the induction multiple after the inducer DOX was added was calculated. The results are shown in Table 4.
[0062] Table 4
[0063] From the above results, it can be seen that the constructed multiple versions of inducible promoters (such as LYR1P068, LYR1P070, LYR1P071, LYR1P074) have lower background leakage expression and higher expression intensity after induction.
[0064] Example 3: Inducing expression of adenoviral genes using inducible promoters (1) Construction of E1A inducible expression plasmid The adenovirus E1A gene (Gene ID: 2652980) expression cassette was cloned and replaced into the LYR1P068 plasmid in Table 3 to replace the Luciferase-P2A-zsGreen expression cassette, and the E1A inducible expression plasmid in Table 5 was constructed. At the same time, the adenovirus E1A original promoter plasmid without TetO was constructed as a reference.
[0065] Table 5
[0066] (2) Detection of E1A-induced expression effect Each version of the E1A inducible expression plasmid in Table 5 was co-transfected with the TetR-Krab regulatory element plasmid in huh7, and the expression of the target gene was compared when the inducer Dox was added after transfection. The results are shown in Figure 5. Figure 3 shown.
[0067] Depend on Figure 3 It can be seen that the constructed inducible promoter has lower background leakage expression and higher expression intensity after induction, which proves that the promoter constructed in this article can achieve the inducible expression of adenovirus genes.
[0068] Incorporated by Reference Each patent and scientific article mentioned herein is incorporated by reference in its entirety for all purposes.
[0069] Equivalence The present disclosure may be embodied in other specific ways without departing from its spirit or essential characteristics. Therefore, the above embodiments should be regarded as illustrative in all cases, rather than limiting the invention described herein. Therefore, the scope of the present disclosure is indicated by the appended claims rather than by the above description, and all changes within the equivalent meaning and scope of the claims are intended to be covered therein.
Claims
1. A modified promoter, compared to an unmodified promoter, wherein a TetO operator is inserted before and / or after the TATA box, wherein the copy number of the TetO operator is more than one, and the unmodified promoter is selected from EF1a, MNDU3, hCEF1, RSV, SV40, E1A, E2A or E4.
2. The modified promoter according to claim 1, wherein Compared with the unmodified promoter, 1) A TetO operator is inserted into 1-2 bp before the TATA box and 2-10 bp after the TATA box, respectively, wherein the copy number of the TetO operator is more than one, and the unmodified promoter is selected from EF1a, MNDU3, hCEF1, RSV or SV40; or 2) A TetO operator is inserted 2-10 bp after the TATA box, wherein the copy number of the TetO operator is more than two, and the unmodified promoter is selected from EF1a, MNDU3, hCEF1, RSV or SV40; or 3) The TetO operator is inserted into the 2 bp before the TATA box and the 2-10 bp after the TATA box, respectively, wherein the copy number of the TetO operator is more than one, and the unmodified promoter is selected from E1A, E2A or E4.
3. The modified promoter according to claim 1 or 2, wherein the nucleotide sequence of the modified promoter is as shown in any one of SEQ ID NOs: 3-19.
4. A nucleic acid construct comprising: (1) Polynucleotide sequence of interest; (2) A transcriptional regulatory element operably linked to a polynucleotide sequence of interest, wherein the transcriptional regulatory element comprises the modified promoter according to any one of claims 1 to 3, and the transcriptional regulatory element is located upstream of the polynucleotide sequence of interest.
5. A vector comprising the modified promoter according to any one of claims 1 to 3 or the nucleic acid construct according to claim 4; Preferably, the vector is a viral vector; more preferably, the viral vector is an AAV vector. The vector according to claim 5 , wherein the viral vector is an adenoviral vector or a lentiviral vector.
7. An adeno-associated virus (AAV) particle comprising the vector of claim 5 and a capsid protein; Preferably, the AAV is selected from the group consisting of wild-type AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrh.8, AAVrh.10, AAVrh.39, AAVHSC15, AAVHSC17 and AAV serotypes modified based on AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrh.8, AAVrh.10, AAVrh.39, AAVHSC15, AAVHSC17. 8 . A cell for producing adeno-associated virus (AAV), comprising the nucleic acid construct of claim 4 or the vector of claim 5 .
9. Use of the modified promoter according to any one of claims 1 to 3, the nucleic acid construct according to claim 4, or the cell according to claim 8 in increasing the level of induced expression of a polynucleotide sequence of interest.
10. A method for inducing expression of a protein of interest in vitro, comprising: The modified promoter according to any one of claims 1 to 3, the nucleic acid construct according to claim 4, or the cell according to claim 8 is used in the presence of an inducing agent to induce expression of a polynucleotide sequence of interest.
